Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369262 | 0.82 | — | — | |
| SCHEMBL6369258 | 0.82 | — | — | |
| SCHEMBL18055629 | 0.80 | PPARG (0.31) | — | |
| SCHEMBL10290622 | 0.72 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL10499893 | 0.70 | — | — | |
| SCHEMBL10499910 | 0.70 | — | — | |
| SCHEMBL216025 | 0.69 | — | — | |
| SCHEMBL31281832 | 0.68 | GRIK1 (0.35) | SMN1; SMN2 | |
| SCHEMBL17674106 | 0.67 | SMN1; SMN2 (0.51) | SMN1; SMN2 | |
| SCHEMBL17674104 | 0.67 | SMN1; SMN2 (0.51) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365517-B2 | 3-cyano-quinoline derivatives with antiproliferative activity | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | disclosed |
| US-20140256948-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| EP-1824856-B1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | disclosed |
| EP-1633365-B1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2305687-A1 | Quinazoline derivatives | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| EP-1696914-B1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-28 | — | — | EP | disclosed |
| EP-1697384-B1 | PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256948-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | NR1H3, NR1H2, NR1D1 | SMN1; SMN2 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.